Arecor Therapeutics (FRA:6UI) Non Operating Income: €0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6UI Arecor Therapeutics PLC FRA:6UI
39 GF Score
Price €0.58
GF Value €0.45
! 6 Warning Signs
View Full Analysis

What is Arecor Therapeutics Non Operating Income?

Arecor Therapeutics FRA:6UI 39 Non Operating Income is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:6UI with a GF Score™ of 39/100 and a GF Value™ of €0.45. The stock has 6 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Arecor Therapeutics's Non Operating Income for the six months ended in Dec. 2025 was €0.00 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.

Arecor Therapeutics Non Operating Income Related Terms

Arecor Therapeutics Non Operating Income Historical Data

* Premium members only.

The historical data trend for Arecor Therapeutics's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arecor Therapeutics Non Operating Income Chart

Arecor Therapeutics Annual Data
Trend May17 May18 May19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Non Operating Income
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Arecor Therapeutics Semi-Annual Data
May17 May18 May19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:6UI
39GF Score
Arecor Therapeutics PLC FRA:6UI
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arecor Therapeutics Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of €0.00 Mil mean?
Arecor Therapeutics (FRA:6UI) has a Non Operating Income of €0.00 Mil as of Dec. 2025. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Arecor Therapeutics and its competitors.
Is Arecor Therapeutics' Non Operating Income too high?
Arecor Therapeutics' current Non Operating Income is €0.00 Mil. Overall, Arecor Therapeutics has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Arecor Therapeutics' Non Operating Income compare to VRTX and REGN?
Arecor Therapeutics' Non Operating Income of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Biotechnology company?
A good Non Operating Income depends on the Biotechnology industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Arecor Therapeutics and its competitors. Arecor Therapeutics's current Non Operating Income is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arecor Therapeutics stock overvalued right now?
Arecor Therapeutics (FRA:6UI) has a current Non Operating Income of €0.00 Mil. The stock's GF Value™ is €0.45, compared to a current price of €0.58 — trading 27.8% above its estimated fair value. The current Non Operating Income is €0.00 Mil. Arecor Therapeutics' overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Arecor Therapeutics (FRA:6UI), the current Non Operating Income is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arecor Therapeutics (FRA:6UI) Overvalued in 2026?

Based on GuruFocus' analysis, Arecor Therapeutics stock appears to be overvalued. The current stock price of €0.58 is trading 27.8% above its estimated GF Value™ of €0.45.

Key valuation signals for FRA:6UI:

  • Non Operating Income: €0.00 Mil
  • GF Value™: €0.45 vs. price of €0.58 (27.8% above fair value)
  • GF Score™: 39/100 with 6 warning signs

No single metric tells the full story. See the FRA:6UI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arecor Therapeutics Business Description

Other Exchanges AREC:UK6UI:Germany
Address Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing medicines to market through the enhancement of existing therapeutic products. By applying an proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Europe (excl. UK) & Middle East, and the USA, out of which the majority is from the Europe (excl. UK) & Middle East.
39GF Score

Get the complete analysis for FRA:6UI

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.58
Price
€0.45
GF Value